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The antimetabolite mercaptopurine (MP) is widely used to treat childhood acute lymphoblastic leukaemia (ALL). To study the
dynamics of MP on the cell cycle, we incubated human T-cell leukaemia cell lines (Molt-4 sensitive and resistant subline and P12
resistant) with 10mM MP and measured total cell count, cell cycle distribution, percent viable, percent apoptotic, and percent dead
cells serially over 72h. We developed a mathematical model of the cell cycle dynamics after treatment with MP and used it to show
that the Molt-4 sensitive controls had a significantly higher rate of cells entering apoptosis (2.7-fold, Po0.00001) relative to the
resistant cell lines. Additionally, when treated with MP, the sensitive cell line showed a significant increase in the rate at which cells
enter apoptosis compared to its controls (2.4-fold, Po0.00001). Of note, the resistant cell lines had a higher rate of antimetabolite
incorporation into the DNA of viable cells (41.4-fold, Po0.01). Lastly, in contrast to the other cell lines, the Molt-4 resistant subline
continued to cycle, though at a rate slower relative to its control, rather than proceed to apoptosis. This led to a larger S-phase block
in the Molt-4 resistant cell line, but not a higher rate of cell death. Gene expression of apoptosis, cell cycle, and repair genes were
consistent with mechanistic dynamics described by the model. In summary, the mathematical model provides a quantitative
assessment to compare the cell cycle effects of MP in cells with varying degrees of MP resistance.
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The thiopurine antimetabolites mercaptopurine (MP) and thio-
guanine are analogues of the purine bases hypoxanthine and
guanine and these medications are a major component of
paediatric acute lymphoblastic leukaemia (ALL) treatment proto-
cols worldwide. After cellular uptake, the first essential activation
step is catalysed by hypoxanthine-guanine phosphoribosyl
transferase (HPRT). Phosphoribosylation activates MP through
the purine ‘salvage pathway’ via TIMP (6-thioinosine-50-mono-
phosphate), and TXMP (6-thioxanthosine-50-monophosphate) to
thioguanine nucleotides (TGNs) which are considered to be the
main active metabolites (Relling et al, 1999). Thiopurine-
S-methyltransferase (TPMT) catalyses S-methylation of MP and
MP-metabolites, that is the main intracellular inactivating path-
way in haematopoietic tissues. However, the most abundant
S-methylated MP metabolite, S-methylthioinosine-50-mono-
phosphate (
meTIMP), inhibits phosphoribosyl pyrophosphate
(PRPP)-amidotransferase, an essential enzyme in the de novo
purine synthesis pathway (DNPS). The MP pathway is given in
Figure 1A, illustrating the above-described enzymes.
Thiopurine cytotoxicity is explained in part by inhibition of
DNPS, which is essential for generating new purines for DNA and
RNA synthesis. However, incorporation of TGNs into DNA
and RNA is generally considered to be the principal mechanism
of MP cytotoxicity. Primarily, 20-deoxy-6-thioguanosine-50triphos-
phate (dG
STP) is incorporated into DNA, subsequently showing a
characteristic delayed cytotoxic effect (Maybaum and Mandel,
1983). Recent studies have shown that the incorporation of dG
sTP
into duplex DNA results in subtle localised modification on DNA
structure (Somerville et al, 2003). Moreover, chromatin structure
alteration is most evident in the G2 phase of the cell cycle
(Maybaum and Mandel, 1983). Enzymes necessary for DNA
replication are affected by MP incorporation into DNA, including
DNA polymerase, DNA ligase I (Ling et al, 1992), topoisomerase II
(Krynetskaia et al, 2000) and RNase H (Krynetskaia et al, 1999).
Furthermore, post-replicative mismatch repair (MMR) proteins
may play a role in MP mechanism of action (Waters and
Swann, 1997). Mismatch repair proteins can ‘tag’ mismatches,
the dG
STP*T pair among them, and futile attempts to repair this
DNA mismatch is thought to trigger apoptosis. More recently,
a novel protein complex containing HMGB1, HMG2, HSP70,
ERp60 and GAPDH has been shown to bind preferentially
to duplex DNA into which a dG
STP has been incorporated
(Krynetski et al, 2003). However, the precise molecular
mechanism(s) of MP cytotoxicity and resistance is not comp-
letely understood.
Acquired or intrinsic drug resistance mechanisms extensively
studied in anticancer treatment are enhanced efflux through
activation of transmembrane proteins, increased detoxifica-
tion (e.g., via activation of glutathione transferases) and activa-
tion of anti-apoptosis or cell cycle arrest through survival
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ssignals such as Bcl-2 or p53. These specific examples have not been
identified as resistance mechanisms to MP in leukaemia, although
in principle they may apply. Previously studied resistance
mechanisms are ABCB1 (MDR1) (Zeng et al, 2004), ABCC4 and
ABCC5 (MRP4 and MRP5) (Reid et al, 2003) and MMR deficiency
(Offman et al, 2004).
Given cell cycle kinetic information including cell cycle phase
distribution and percentage of cells in apoptosis, mathe-
matical models can be used to test hypotheses on the mechanism
of action of the drug and to point to possible drug-resistance
mechanisms. Mathematical models have been previously used
to understand dose dependency of cell cycle dynamics and to
quantitate differences in cell cycle block and apoptosis of an
experimental anti-mitotic agent (Kozusko et al, 2001). The
objective of the current study is to investigate, via mathematical
models and gene expression analysis, the effects of MP on the
cell cycle dynamics of three ALL cell lines that differ in their
sensitivity to MP.
De novo purine synthesis
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Figure 1 (A) Mercaptopurine metabolic pathway. Intracellular mercaptopurine (MP) is converted into thioinosine monophosphate (TIMP) by
hypoxanthine-guanine phosphoribosyl transferase (HPRT), using 5-phospho-D-ribose-1-pyrophosphate (PRPP). TIMP is converted into thioxanthosine
monophosphate (TXMP), then to thioguanosine monophosphate (TGMP), by inosine monophosphate dehydrogenase (IMPDH) and guanine
monophosphate synthetase (GMPS). TGMP can be converted into thioguanine nucleotide diphosphate (TGDP) and triphosphate (TGTP). Cytotoxic
effects occur when TGN is incorporated into DNA or RNA or when methylthioinosine monophosphate (MeTIMP) inhibits de novo purine synthesis. The
inactivation of MP is catalysed by xanthine oxidase (XDH), thiopurine methyltransferase (TPMT) or adenosine kinase (ADK). Alternative products are
mercaptopurine riboside (rMP), methylmercaptopurine (MeMP), methylmercaptopurine riboside (rMeMP). Enzymes are shown in circles and metabolites in
boxes, underlined are metabolites detected in our assay. (B) TPMT and HPRT activity are listed for the three cell lines. (C) DNPS inhibition following MP
treatment was measured in three cell lines at the sampling hours indicated. (D) Shows intracellular MP metabolite concentration in the three cell lines P12
resistant, Molt-4 resistant, and Molt-4 sensitive at the sampling hours indicated. Measured were MP, rMPþTIMP, all thioguanine nucleotides (TG),
rMeMPþMeTIMP.
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sMATERIALS AND METHODS
Cell lines
Two human T-cell leukaemia cell lines were used, that are commer-
cially available, representing MP sensitivity: Molt-4 (American
Type Culture Collection, Rockville, MD, USA) and MP resistance:
P12 (German Collection of Microorganism and Cell Cultures,
Braunschweig, Germany) and a subline of Molt-4 that was not
intentionally selected for MP resistance. The media consists of 89%
RPMI 1640, 1% L-Glutamine, 200mM (BioWhittaker, Walkersville,
M D ,U S A ) ,a n d1 0 %f e t a lb o v i n es e r u m( H y C l o n e ,L o g a n ,U T ,U S A ) .
Mercaptopurine treatment
In each experiment, MP (Sigma, St Louis, MO) stock solution was
freshly prepared. Cells of 0.5 to 1 10
6cellsml
 1 density were
incubated in 10mM final concentration of MP for 12, 24, 48, and 72
hours at 371Ci n5 %C O 2. The IC50s (concentration that inhibits
50% of cell growth relative to controls) for the three cell lines for
the 24-h MP exposure was determined by flow cytometric analysis.
Flow cytometric analyses
To measure total cell count, cell cycle distribution, percent viable,
percent apoptotic, and percent dead cells, cells were stained with
annexin-V and propidium iodide (PI) and analysed by flow
cytometry (FACS) with the Coulter EPICS-V flow cytometer
(Coulter Electronics Inc., Hialeah, FL, USA). The computer
program PEAK was used to calculate the percentages of cells in
the G0/G1, S, G2/M phase. Controls without MP were also run for
each cell line at the same sampling times.
Mathematical modelling
The model developed here is a modification of a previous model of
cell cycle dynamics used to describe a M-phase specific anticancer
agent (Kozusko et al, 2001). These modifications account for the
unique dynamics of MP and the specific form of the experimental
results available in this study, that is, total cell count, percent
G0/G1-phase, percent S-phase, percent G2/M-phase, percent
viable, percent apoptotic, and percent non-viable. Figure 2 shows
the dynamics of the model, which is described by the following
system of ordinary differential equations:
Viablephase
Cellsfreeof TGNincorporation
dG
dt ¼  aSG þ 2bM
dS
dt ¼ aSG  ð aM þ g1ÞS
dM
dt ¼ð 1   fÞaMS   bM
8
> <
> :
TGNincorporatedcells
dMI
dt ¼ famS þ aMISI   bIMI
dGI
dt ¼  aSIGI þ 2bIMI
dSI
dt ¼ aSIGI  ð gMP þ aMIÞSI
8
> > <
> > :
2
6 6 6 6 6 6 6 6 6 6 4
Apoptoticphase
dA
dt
¼ g1S þ gMPSI   g2A
 
Non   viablephase
dN
dt
¼ g2A   g3N
 
The variables are as follows: G, number of cells in G0/G1-phase; S,
number of cells in S-phase; M, number of cells in G2/M-phase; GI,
SI, and MI are the equivalent variables for the TGN incorporated
phases; A, apoptotic cells; N, non-viable cells. All the parameters
describe the rate of transition (1/hour) between phases.
1
aS
þ
1
aM
þ
1
b
¼ CCT
CCT is the cell cycle time (defined in terms of transition rate
parameters in the above equation) in hours; aS, aSI, b, bI, aM, and
aMI all describe transition rates between cell cycle phases; fA[0,1]
describes the fraction of cells that continue through the cell cycle at
least one more cycle after TGNs were incorporated into their DNA
before going through apoptosis (its magnitude is an indication of
S-phase block efficiency); g1 and gMP describe the transition rate
of S and SI-phase cells to apoptosis, respectively; g2 describes the
transition rate of apoptotic cells to the non-viable state; and g3
describes the transition rate out of the non-viable state.
Parameter estimation
To estimate the parameters, the model was first fit to the control
data for each of the cell lines to obtain estimates for the model
parameters aS, b, aM, g1, g2, and g3. In all cases, CCT was fixed
(which in turn set b) to allow a unique solution for the remaining
parameters. Once these parameters were obtained, aS, b, and aM
were fixed and the remaining parameters were estimated using the
MP-treated data. In all cases, the maximum likelihood parameter
estimation method as implemented in ADAPT II (D’Argenio and
Schumitzky, 1997) was used. Parameter estimation accuracy was
given in terms of the coefficient of variation (CV in percent).
Comparisons between control and treated parameters and between
cell lines were made using the t-test.
Gene expression profiling
Molt-4 sensitive and Molt-4 resistant cells were also subjected for
gene expression analysis. RNA of 5 10
6 cells was isolated by
phenol/guanidine thiocyanate extraction using TRI REAGENT
(Molecular Research Center, Cincinnati, OH, USA). High-quality
cRNA was hybridised to the HG-U95Av2 oligonucleotide micro-
array, which contains 12599 gene probe sets, representing
approximately 9670 known genes, plus approximately 1495 EST
clones (Affymetrix, Santa Clara, CA, USA). Scaled gene expression
values for pretreatment, post-treatment (10mM MP for 24 hours)
and fold-change (post-treatment vs pretreatment ratio) were
calculated using the default settings of Affymetrix Microarray
Suite software version 5 (MAS 5.0) (Cheok et al, 2003). Pathway
genes were selected using Netaffx. Pathway analysis was performed
using Ingenuity software (http://www.ingenuity.com). The probe
sets were mapped to the corresponding gene within the Ingenuity
Pathway Knowledge Base.
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G2/MI
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G2/M S 
A 
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Figure 2 Schematic of mathematical model describing the dynamics of
MP. The variables and parameters are defined in the text.
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sRESULTS
To compare the relative resistance among the three leukaemia cell
lines we determined the IC50s after 24-hours incubation with MP:
Molt-4 sensitive, 6–10mM; P12, 450mM; and Molt-4 resistant,
450mM. Initial TPMT and HPRT activity were measured and no
difference was found for HPRT activity, for P12 cells TPMT activity
was higher compared with the other lines (Figure 1B) (Dervieux
et al, 2001). DNPS inhibition after MP exposure is a mechanism
that may contribute to cytotoxicity, but was not found different
in these three cell lines (Figure 1C) (Dervieux et al, 2002).
Additionally, intracellular metabolites of MP were measured
(Dervieux et al, 2002) (Figure 1D) and drug resistance cannot be
attributed to reduced uptake of MP (Figure 1D, top panels) or
lower level of active metabolites (TGN), as the sensitive Molt-4 in
fact accumulates lower level of TGN compared to the resistance
cell lines (Figure 1D, Panel TG). Molt-4 resistant cells accumu-
late higher level of methylated metabolites (Figure 1B, Panel
rMeMP, MeTIMP) in contrast to the other resistant cell line P12
or to the sensitive Molt-4. Therefore, we anticipate differences in
cell cycle dynamics related to mechanisms other than DNPS or MP
metabolism in these three lines.
Using the model described in Figure 2, each of the three cell
lines we considered showed distinct dynamics. These are
illustrated in Figures 3 and 4, where the experimental data is
shown along with the model fit. The parameter estimates for all the
fits are given in Table 1. Models other than the one described were
also considered, but they were inadequate in describing the data.
For example, one model considered fixing f¼0 which means that
once TGNs are incorporated into the cells, cells immediately enter
apoptosis. However, with this assumption, the model did not
describe the block in S-phase appropriately and failed in particular
to describe the 12–24 hour delay in the initiation of the cell cycle
block (data not shown).
To better understand the different dynamics between these cell
lines, we focused on the parameters that either exhibit large
changes between the control and MP-treated states or exhibit large
changes among cell lines. There were three main parameters (or
groups of parameters) where we observed significant differences.
These included the parameters representing apoptosis (g1, g2, g3,
and gMP), the parameter representing TGN incorporation (f), and
lastly, the parameters representing the viable cell dynamics after
TGN incorporation (aSI, bI, and aMI). Differences in these model
parameters are indicative of the different mechanisms of action of
MP in the cell lines studied.
When considering the untreated state for each cell line, the
MP-sensitive cell line (Molt-4 sensitive) had a significantly higher
rate of cells entering apoptosis (g1, 2.7 and 3.3-fold, Po0.00001),
transiting through apoptosis to the non-viable phase (g2, 2.9 and
4.3-fold, Po0.00001), and eliminating from the non-viable phase
(g3, 2.8 and 4.0-fold, Po0.00001) relative to the resistant cell lines
(P12 and Molt-4 resistant). When treated, the sensitive cell line
(Molt4 sensitive) showed a significant increase, compared to the
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scontrol, in the rate at which cells immediately enter apoptosis
after TGN incorporation (g1, increased 2.4-fold, Po0.00001). In
addition, the rate of apoptosis in viable cells with incorporated
TGN was highest in Molt-4 sensitive, intermediate in P12 and
lowest in Molt-4 resistant cells (gMP for Molt-4 sensitive 1.7
and 1.9-fold higher, Po0.00001, relative to P12 and Molt-4
resistant cells).
When treated with MP, the model parameters indicated that the
more resistant cell lines (P12 and Molt-4 resistant) had a higher
rate of TGN incorporation into the DNA of viable cells (f, increased
1.4 and 2-fold, Po0.01) relative to the Molt-4 sensitive cell line.
This is in line with the experimental results on TGN incorporation
in Figure 1D, Panel TG. Both P12 and Molt-4 sensitive cell lines
completed only one additional cell cycle after MP exposure (with a
time to complete the additional cycle of 9.4 and 7.8 hours,
respectively) before proceeding to apoptosis (aMI¼0) and showed
similar S-phase blocks (related to no significant difference in aSI).
In contrast, the Molt-4 resistant subline continued to cycle
(aMI40, Po0.00001), though at a rate eight times slower relative
to the controls (aM/aMI¼8, Po0.00001). This led to a cell cycle
time (CCT) in the TGN-incorporated cells that were 3.9 times
slower then their controls. This, along with the above-mentioned
lower rate of apoptosis in viable cells with TGN incorporated, led
to a larger S-phase block in the Molt-4 resistant cell line, but not a
higher rate of cell death.
Gene expression analysis pre- and post-treatment was per-
formed on Molt-4 resistant and Molt-4 sensitive cells. We extracted
all gene probe sets from the U95Av2 microarray that were involved
in the purine pathway (n¼103), cell cycle regulation (n¼561),
apoptosis (n¼407) or repair (n¼192), based on the NetAffxt
analysis center database (http://www.affymetrix.com). Of these 241
were duplicates, 24 were not detected in all four chips (absent by
Table 1 Model parameter estimates
P12 Molt-4 sensitive Molt-4 resistant
Parameter Control Treated Control Treated Control Treated
aS 0.1559 (4.8)
a 0.1588 (4.0)
a 0.1182 (3.8)
a
aM 0.0941 (3.3)
a 0.1388 (3.7)
a 0.1238 (4.1)
a
CCT
b 20.0 15.0 18.0 70.8
g1 0.0184 (11.6)
a NSC* 0.0503 (5.5)
a 0.1210 (10.0)
a 0.0152 (15.6)
a NSC*
g2 0.1438 (18.2)
a NSC* 0.4118 (11.8) 0.0829 (6.1) 0.0956 (25.5)
a 0.1555 (9.2)
a
g3 0.1064 (23.3)
a NSC* 0.2915 (11.3) 0.0485 (8.7)
a 0.07329 (37.3)
a 0.1045 (10.7)
a
f 0.7277 (3.4)
a 0.5080 (7.7)
a 1.0
aSI NSC* NSC* 0.2289 (10.1)
a
aMI 0 0 0.0154 (15.3)
a
gMP 0.0671 (6.9)
a 0.0758 (9.0)
a 0.0402 (7.5)
a
aCoefficient of variation (%).
bCell cycle time (h). *No significant change.
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Figure 5 Pathway analysis of genes that were differentially expressed in resistant compared to sensitive Molt-4 ALL cells. Arrows indicate genes discussed
in the text. Forty-three probe sets (28 unique genes) were differentially expressed between resistant and sensitive Molt-4 ALL cells or changed expression
before and after treatment with MP in resistant compared to sensitive Molt-4 ALL cells. These genes served as the input for the pathway query. Two
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sAffymetrix detection call), and 763 did not show a significant
change in all three comparisons (no change by Affymetrix change
call). Figures 5 and 6 summarise the results indicating the genes
with relative changes (450%) checked by absolute changes (signal
4500) along with a graphical description of the pathway analysis.
In summary, pro-apoptotic genes were under-expressed in Molt-4
resistant compared to Molt-4 sensitive (e.g., BAX, RTN4, CD2),
upregulated after MP treatment in Molt-4 sensitive (e.g., BAX,
BCLAF1) and downregulated after MP treatment in Molt-4
resistant cells (e.g., PDCD2, PDCD6). In contrast, anti-apoptotic
genes were overexpressed in resistant cells compared to sensitive
cells (CASP2) and upregulated in MP-resistant cells after treatment
with MP (e.g., MCL1, TNFRSF6). Of the genes involved in cell cycle
regulation cyclin B1, B2, E2 and RB 1 were overexpressed in
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sresistant cells and cyclin E2 and CDK6 were induced in sensitive
cells after treatment with MP. Lastly, repair genes were over-
expressed in resistant cells compared to sensitive cells (e.g.,
MSH2, BLM), downregulated after treatment (e.g., PCNA, XRCC5)
or upregulated (PMS2L3, 5, 6) in resistant cells or upregulated
after treatment in sensitive cells (e.g., GADD45A, ERCC6,
RAD17, MSH2).
DISCUSSION
The mathematical model of the cell cycle dynamics of MP
described in this study is useful to test hypotheses related to
potential causes of drug resistance to MP. In particular, it
illuminated differences in resistance to MP based on altered
growth dynamics among cell lines during treatment with MP. The
model is particularly useful in understanding dynamics, which are
not intuitive from the experimental data. Our model focuses on
MP resistance owing to alterations in cell cycle regulation.
One finding of our model is that the P12 cell line and the
resistant Molt-4 subline arrest efficiently in S-phase after
incorporating MP but have a lower rate of cells entering apoptosis
relative to the MP-sensitive Molt-4 cell line. Furthermore, the
resistant Molt-4 subline has the ability to continue cycling after
incorporation of TGN without going into apoptosis. This suggests
that in this resistant cell line, the mechanism of resistance is not a
lack of TGNs being incorporated into the DNA, but rather a faulty
mechanism which does not detect incorporated TGNs and/or
faulty mechanism of signaling apoptosis. These dynamics point
to a possible defect in detecting the DNA/RNA damage. Thus,
extended S-phase arrest is possibly an indication of MP resistance.
These observed differences in apoptosis may be owing to
alterations in the MMR system (e.g., MSH2 (Krynetskaia et al,
2003)) Sensitive cell lines may have higher expression of these
proteins or may induce expression after treatment more efficiently;
they may be absent in resistant cell lines or may reduce expression
after treatment. In fact, expression array data show a larger
increase of MSH2 expression in the Molt-4 sensitive cell line
compared to the resistant subline (after treatment relative to
controls, Figure 6). Thus, if the MMR system is not functioning
appropriately in the resistant cell lines then, as the model predicted
and as gene expression confirmed, TGNs may be incorporated into
the DNA but because these cells lack mismatch detection it
continues to remain viable as opposed to entering apoptosis as the
sensitive cells do.
Additionally, decreased pro-apoptotic signalling in Molt-4
resistant compared to Molt-4 sensitive (e.g., BAX, RTN4, CD2),
downregulation after MP treatment in Molt-4 resistant cells (e.g.,
PDCD2, PDCD6) and upregulation after MP treatment in Molt-4
sensitive (e.g., BAX, BCLAF1) point to decreased apoptosis in the
Molt-4 resistant increased apoptosis in the Molt-4 sensitive cells
pre- and post-treatment, as presented by the model. Consistent
with these findings was the expression of genes involved in anti-
apoptotic signalling as they were overexpressed in resistant cells
compared to sensitive cells (CASP2) and upregulated in MP-
resistant cells after treatment with MP (e.g., MCL1, TNFRSF6).
Lastly, continuation of cycling of Molt-4-resistant cells may be
due to cyclin B1, B2, E2 and RB 1 that were overexpressed in
resistant cells and downregulation of PCNA after MP treatment
compared to sensitive cells.
The results of our modelling study point to key regulators in the
cell cycle signalling pathway that pharmacodynamically affect
sensitivity and/or resistance of ALL cells to MP.
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